Image credit: Canva
Many cancer cells produce substances called antigens that are unique to each cancer. One method of treating such cancers is taking disease-fighting white blood cells from a person, changing those cells so they will target the cancer cell antigens, and returning them to that person’s blood. Researchers want to know if a vaccine may help these modified white cells work better. A trial led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, is researching this combination therapy for certain cancers that have spread throughout the body (metastatic cancers).
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact the NCI SB Immunotherapy Recruitment Center at (866) 820-4505 or irc@nih.gov
Clinicaltrials.gov identifier: NCT06253520
NCI Protocol ID: IRB001662
Official Title: A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow, treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
